Skip to content
FAP News Today logo
  • About FAP
    What is FAP?
    Symptoms
    Diagnosis
    Causes
    Life expectancy and prognosis
  • Treatments
    Approved treatments
    Experimental treatments
  • News
  • Columns
    Rumination and Response — Ezekiel Lim
    Sunrise Sunset — Jaime Christmas
  • Health insights
  • FAQs
  • What can we help you find today?

May 21, 2019 News by Ana Pena, PhD

#AANAM – Tegsedi Continues to Benefit FAP Patients for up to Two Years

Tegsedi (inotersen) continues to slow progression of familial amyloid polyneuropathy (FAP) and maintains the same safety profile over two years of treatment, results of an open-label extension study show. A greater efficacy of the treatment was seen…

Recent Posts

  • Forging relationships at an amyloidosis conference
  • New MRI technique may help detect nerve damage in FAP: Study
  • Amvuttra gets EU approval to treat adults with ATTR-CM
  • Researchers develop quick test for finding genetic mutation
  • MRI parameter may be new FAP biomarker, study suggests


Bionews, Inc.

3 W Garden St
Suite 700
Pensacola, FL 32502
Website: bionews.com
Email: info@bionews.com
Phone: 1-800-936-1363

  • About Us
  • Leadership
  • Our Culture
  • Editorial Policy
  • Advertising Policy
  • Corrections Policy
  • Terms of Service
  • Privacy Policy
  • Careers
  • Contact Us
Disclaimer

This site is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.

Copyright © 2013-2025 All rights reserved.